Enhanced Neointima Formation Following Arterial Injury in Immune Deficient Rag-1−/− Mice Is Attenuated by Adoptive Transfer of CD8⁺ T cells

Paul C. Dimayuga*, Kuang-Yuh Chyu, Jonathan Kirzner, Juliana Yano, Xiaoning Zhao, Jianchang Zhou, Prediman K. Shah, Bojan Cercek

Division of Cardiology, Oppenheimer Atherosclerosis Research Center, Cedars-Sinai Heart Institute, Los Angeles, California, United States of America

Abstract

T cells modulate neointima formation after arterial injury but the specific T cell population that is activated in response to arterial injury remains unknown. The objective of the study was to identify the T cell populations that are activated and modulate neointimal thickening after arterial injury in mice. Arterial injury in wild type C57Bl6 mice resulted in T cell activation characterized by increased CD4⁺CD44hi and CD8⁺CD44hi T cells in the lymph nodes and spleens. Splenic CD8⁺CD25⁺ T cells and CD8⁺CD28⁺ T cells, but not CD4⁺CD25⁺ and CD4⁺CD28⁺ T cells, were also significantly increased. Adoptive cell transfer of CD4⁺ or CD8⁺ T cells from donor CD8⁻/− or CD4⁻/− mice, respectively, to immune-deficient Rag-1−/− mice was performed to determine the T cell subtype that inhibits neointima formation after arterial injury. Rag-1−/− mice that received CD8⁺ T cells had significantly reduced neointima formation compared with Rag-1−/− mice without cell transfer. CD4⁺ T cell transfer did not reduce neointima formation. CD8⁺ T cells from CD4⁻/− mice had cytotoxic activity against syngeneic smooth muscle cells in vitro. The study shows that although both CD8⁺ T cells and CD4⁺ T cells are activated in response to arterial injury, adoptive cell transfer identifies CD8⁺ T cells as the specific and selective cell type involved in inhibiting neointima formation.

Introduction

Clinical evidence suggest that the T cell immune response is involved in restenosis, the process of re-narrowing of the artery after percutaneous coronary intervention (PCI), but the specific T cell subtypes involved remain to be elucidated [1–3]. Current understanding of immune function in the vascular wall is based mostly on alloreactive responses, but little is known about syngeneic T cell responses, which is presumably what would happen in the immune response to arterial injury. This is a significant issue considering that options to treat restenosis include the use of immune-suppressing drugs [4–6]. In addition, there is the possibility of persistent immune activation after PCI [7].

Specific immune activation signals after arterial injury remain undefined but sources of non-antigen specific signals include release of intracellular material such as uric acid by injured cells [8], or adjuvant-like activity by heat shock proteins [9]. In addition, lipid neoantigens produced after arterial injury may be important signaling molecules [10].

Neointimal thickening is the underlying mechanism that drives restenosis and recent experimental reports suggest that T cell recruitment into the arterial wall promotes the process [11–13]. On the other hand, experimental studies have also demonstrated that neointima formation is significantly augmented in immune-compromised animals, specifically those with T cell deficiency [14–18]. We have previously reported that adoptive transfer of T cells into immune-deficient Rag-1−/− mice reduced neointima formation [16]. Common to all these reports is the involvement of T cells in neointima formation. However, the T cell response to arterial injury is not well characterized and its kinetics undefined. Natural killer (NK) T cells augment neointima formation [10] but it remains unclear if other subsets of T cells play defined roles in the response [6]. It is thus important to identify which T cells are involved in modulating the response to vascular injury.

We provide evidence that arterial cuff injury results in T cell immune activation, characterized by a robust CD8⁺ T cell response. To help elucidate the T cell subset(s) involved in neointima formation after vascular injury, we used adoptive transfer of CD4⁺ or CD8⁺ T cells to immune-deficient Rag-1−/− mice [19]. The adoptive transfer model allowed for the direct study of the role of distinct subsets of immune cells. We have reported that B cells and immunoglobulin reduce neointima formation after arterial injury [15,20]. Thus, to test the role of specific T cell subsets, adoptive transfer of specific T cell subtypes provided the best approach to exclude the effect of B cells. The results show that CD8⁺ T cells are likely the subtype involved in inhibiting neointima formation.
Results

Characterization of T cell response to arterial injury in WT mice

To characterize the specific T cell population activated after arterial injury, we performed flow cytometric analysis on cells in the regional lymph nodes and spleen at various time points after injury. We used previously reported activation markers, namely: CD69, CD28, CD25, and CD44 [10,21–23].

CD4+ T cells after arterial injury. There was no significant increase in CD4+CD69+ T cells in the lymph nodes and spleens after injury (not shown), as previously reported [10]. CD4+CD44hi T cells in the lymph nodes (Fig. 1A, top panel) and spleen (Fig. 1A, bottom panel) of WT mice significantly increased 7 days after injury. Twenty-one days after injury, CD4+CD44hi cells decreased back to uninjured levels (Fig. 1A and Table 1). CD4+CD25+ and CD4+CD28hi T cells did not significantly change after injury (Table 1). The sham group did not have significant changes in CD4+ T cells (Fig. 1A and Table 1).

CD8b+ T cells after arterial injury. There was no significant increase in CD8b+CD69+ T cells in the lymph nodes and spleens after injury (not shown). CD8b+CD44hi cells in the lymph nodes

Figure 1. Lymph node and splenic CD44+ T cells after arterial injury in WT mice. Representative scatter plots of lymph node (LN) and spleen cells collected at various times after injury and characterized using CD44 gated on CD4 (A) or CD8b (B). Cells were collected from uninjured (UI) mice, or 7 days (D7) and 21 days (D21) after arterial injury. Sham mice correspond to 7 days after sham surgery. Percentage of cells is indicated on the top right corner of each graph.

doi:10.1371/journal.pone.0020214.g001
Table 1. T cell activation after arterial injury.

|        | UI       | D7       | D21       | Sham      |
|--------|----------|----------|-----------|-----------|
| LN CD4+CD44hi | 13.7±3.2 | 19.1±2.0* | 11.5±1.1  | 12.0±1.4  |
| Spl CD4+CD44hi | 15.5±4.2 | 22.1±2.1** | 11.0±1.7  | 13.6±1.2  |
| Spl CD4+CD25+ | 10.7±4.1 | 12.6±3.0  | 10.5±3.5  | 11.1±0.5  |
| Spl CD4+CD28+ | 90.9±2.7 | 93.0±5.0  | 93.3±3.4  | 93.7±0.9  |
| LN CD8b+CD44hi | 9.0±1.0  | 38.9±13.0** | 9.9±0.8   | 10.6±1.0  |
| Spl CD8b+CD44hi | 8.4±2.7  | 15.6±3.2  | 10.4±2.5  | 9.6±1.0   |
| Spl CD8b+CD25+ | 2.3±0.8  | 6.7±3.0   | 5.9±2.4   | 2.2±0.5   |
| Spl CD8b+CD28+ | 79.3±6.2 | 91.5±23.1† | 90.9±33.1† | 83.7±2.3 |

LN = lymph nodes, N=3; Spl = spleen, N=5. UI= Uninjured mice; D7 and D21 = 7 days and 21 days after arterial injury, respectively. All values expressed as percent CD4+ or CD8b+ gated cells.

*p<0.05 vs. other time points; **p<0.01 vs. other time points;
*p<0.05 vs. UI;
*p<0.05 vs. sham.

doi:10.1371/journal.pone.0020214.t001

Transferred CD8+ T cells in the injured artery

Immuno-histochemical staining showed presence of CD86+ cells in the neointimal layer of Rag-1+CD8 mice (Fig. 5A). Staining of consecutive sections showed presence of CD86+ cells in close proximity to active caspase-3 stain (Fig. 5B) suggesting cytotoxic activity of the CD86+ T cells.

Characterization of adoptively transferred CD8+ T cells

Spleen cells were collected from donor mice (designated as Donor CD86+), uninjured recipient mice 48 hours after T cell transfer (UI), or recipient mice 21 days after injury (D21). Donor cells were aliquoted from the pooled donor spleens before adoptive transfer. Spleens from 2–3 uninjured recipient mice were pooled due to the small size of spleens, whereas individual spleens were used for the D21 time point. Cells were enriched for T cells and flow cytometric analysis was performed. CD86+CD62L+ T cells were unchanged in uninjured recipient mice compared with donor T cells but were significantly reduced 21 days after injury (Fig. 7B). CD86+CD44hi T cells increased in uninjured mice and significantly increased further D21 after injury (Fig. 7C).

Homeostatic T cell expansion in CD8+ T cell recipient mice

Although the changes observed in the transferred CD8+ T cells suggested activation after injury, homeostatic T cell proliferation also occurred as a consequence of cell transfer, which has been demonstrated in recipients that are immune-deficient [24,25]. Homeostatic CD8+ T cell expansion is dependent on MHC-I signaling [24,25]. To test if the reduction in neointima formation is dependent on homeostatic CD8+ T cell expansion, we used a monoclonal antibody to block MHC-I signaling in the recipient mice. Flow cytometric analysis showed that antibody treatment significantly reduced the percentage of CD86+ T cells in the spleen, suggesting that homeostatic T cell expansion was significantly reduced (Table 3). CD86+CD44hi T cells in the spleen were also significantly reduced by antibody treatment but CD86+CD62L+ T cells were not significantly different (Table 3). CD8+ T cell recipient Rag-1+ mice treated with MHC-I monoclonal antibody (mAb) or its isotype control still had reduced neointima formation (0.0125±0.004 mm², N=6 and 0.0142±0.002 mm², N=5 respectively) compared with Rag-1+ mice without cell transfer (0.021±0.009 mm², Table 1; p<0.05 vs. mAb treatment). The reduction in neointima formation was to a similar extent as untreated CD8+ T cell recipient mice (see Table 2).

The results showed that even as MHC-I antibody treatment decreased in Rag-1+CD8 compared with Rag-1+ mice (Table 2). Rag-1+ mice that received CD4+ T cells (Rag-1+CD4; Figure 4F and G) had similar neointima area and intima/media ratio (Table 2) compared with Rag-1+/− mice without T cell transfer. There were no significant differences in vessel size as determined by external elastic lamina area (Table 2). We had previously reported that adoptive T cell transfer into Rag-1+ mice reduced neointima formation after arterial injury [16]. The current results indicate that CD90+ T cells are the cell type involved in the T cell inhibition of neointima formation.
significantly reduced homeostatic CD8+ T cell expansion in the recipient mice, inhibition of neointima formation by CD8+ T cells was not significantly affected.

CD8+ T cells from WT donors also reduced neointima formation

CD8+ T cells from CD4−/− mice have been reported to be contaminated by an atypical MHC-II restricted population [26]. To ascertain whether the reduction in neointima formation by adoptive cell transfer of CD8+ T cells into Rag-1−/− mice was due to this atypical population from CD4−/− mice, we used WT mice as donors instead. WT CD8+ T cell transfer significantly reduced neointima area in recipient Rag-1−/− mice compared with Rag-1−/− mice without cell transfer (0.014±0.008, N=12 vs. 0.021±0.009 mm², N=13, respectively; P<0.05). Intima:media ratio was also significantly reduced by WT CD8+ T cell transfer compared with Rag-1−/− mice without cell transfer (0.32±0.15 vs. 0.54±0.21, respectively; P<0.01). The results further support the finding that CD8+ T cells reduce neointima formation.

Discussion

The results of our study provide the following key findings: 1) T cells are activated and respond to arterial injury; 2) CD8+ T cells have a more robust and sustained response; 3) adoptive transfer of T cell subtypes identify specific CD8+ T cell function in response to arterial injury; and 4) the effector function of CD8+ T cells in arterial injury involves the cytotoxic response. In addition, we also provide supporting evidence that the specific role of CD8+ T cells in our adoptive cell transfer studies is not dependent on homeostatic proliferation, or on an atypical CD8+ T cell population from the CD4−/− donor mice.
There is currently a lack of studies that define T cell response to injury. This is highlighted by the current dilemma in the use of drug-eluting stents coated with immune-suppressants to treat restenosis post PCI. The treatment has been suggested to result in incomplete healing of the injured artery [4,5], a process which remains incompletely understood, suggesting that the immune system regulates vascular tissue homeostasis after injury [6]. Previous reports indicate that T cells inhibit neointima formation after arterial injury [14,16,18], although conflicting results have been reported [10–13]. These findings underscore the need to define the T cell response to arterial injury. We did not observe an increase in CD69+ T lymphocytes after arterial injury, similar to another report [10]. However, flow cytometry using CD44, CD28, and CD25 suggested that both CD4 and CD8 T cell activation occurs after arterial injury in the WT mice. The activation phenotypes observed appear to be the specific result of injury to the carotid artery since the pattern of activation was not observed in the sham group.

Previous characterization of our injury model showed the endothelial lining of the intima sloughing off within a week [20]. Capture and processing of apoptotic and necrotic cells occur in the lymph nodes and spleen through phagocytosis by dendritic cells and macrophages which then signal either immune activation or tolerance [27]. Thus, presentation of, and activation in response to self-antigens would predictably occur at these sites and our results support this notion. Our results further suggest that CD4+ T cell activation was rather transient, yet CD8+ T cell activation was robust and sustained. Immuno-histochemistry identified the local presence of both T cell subtypes in the carotid arteries 21 days after injury, supporting the previously reported involvement of T cells in inhibiting neointima formation [14,16,18].

We assessed the specific role of sub-populations of T cells using immune deficient Rag-1−/− mice as recipients of adoptive T cell transfer and show that CD8+ T cells are the primary T cell type involved in reducing neointima formation. Several reports indicate that immune deficiency in the Rag−/− mouse model results in augmented neointima formation after arterial injury [15–17,20]. The adoptive transfer approach we used was designed to show that any effect of a T cell sub-type in a combined immune-deficient recipient such as the Rag−/− mouse would be specific to that T cell sub-type since Rag−/− mice have no mature T cells and B cells. The presence of B cells or immunoglobulins would complicate the interpretation of the role of specific T cell types given our previous report on the role of B cells and natural antibodies in neointima formation [15,20]. Separate experiments need to be designed to address the possible role of the interaction between specific T cell subsets and B cells in the setting of arterial injury and neointima formation. The results of the adoptive transfer experiments show that CD8+ T cells are directly and specifically involved in limiting neointima formation. To our knowledge, this is the first study to show direct evidence of this specificity. It is also clear from our studies that specific arms of the immune system differentially respond to, and affect neointima formation [15,16,20].

Our results suggest that cytotoxic activity against SMCs is at least one mechanism involved in the CD8+ T cell response after injury. Immuno-histochemical staining of arteries of recipient Rag−/− mice shows CD8b+ cells in close proximity to active caspase-3 positive cells, suggesting cytotoxic activity. The in vitro co-culture experiment supports the cytotoxic pathway of control of SMCs by CD8+ T cells in the injured arterial wall. However, it is also worth noting that syngeneic SMC lysis by CD8+ T cells was not in the magnitude of what is observed in an allogeneic response, suggesting that only a small number of SMCs are targeted by CD8+ T cells.

Our results also show that the process of adoptive transfer by itself results in CD8+ T cell phenotypic change, evidenced by increased CD8+CD44hi cells. This has been attributed to homeostatic expansion of the transferred cells [24,25]. The lack of change in CD8+CD62L− cells by adoptive transfer by itself is in agreement with the reported effect of homeostatic cell expansion on cell phenotype [25]. There appears to be either further immune activation as a result of arterial injury, or continuous homeostatic cell expansion, since CD8+CD44hi T cells increased further and CD8+CD62L− cells decreased at the day 21 time point.

The observation that phenotype change associated with homeostatic CD8+ T cell expansion had occurred led us to test if the effect on neointima formation was directly due to this process. Homeostatic T cell expansion after adoptive transfer into immune-deficient recipients is MHC-I dependent [24,25]. Treatment of the recipient mice with an anti-MHC-I monoclonal antibody partially suppressed homeostatic expansion, reducing the CD8+CD44hi T cells by about half yet still reducing neointima formation, suggesting that the effects of transferred CD8+ T cells
Figure 4. Adoptive T cell transfer. Representative histogram of CD8⁺ T cells homing into the spleen of a recipient mouse 48 hours after cell transfer, before arterial injury (A). Viable lymphocytes were gated on the FSC/SSC plot. Representative sections of 21-day injured carotid arteries (400× magnification) stained with hematoxylin and eosin from Rag-1⁻/⁻ mice (B), Rag-1⁻/⁻ injected with CD8⁺ T cells (D), and Rag-1⁻/⁻ mice injected with CD4⁺ T cells (F). Boxed area indicates magnification of the respective cross-sections (C, E, G). Arrows indicate internal elastic lamina. Bar = 50 microns. doi:10.1371/journal.pone.0020214.g004
on neointima formation are at least partially independent of homeostatic expansion. The transfer experiments also suggest that CD4\(^+\) T cells have no direct role in modulating neointima formation. Although the result is unexpected given the pathogenic role of CD4\(^+\) T cells in lipid-rich atherosclerotic plaques [28], there is yet to be a definitive report on its role in arterial injury. There is the predominant yet untested speculation that CD4\(^+\) T cells are directly involved in neointima formation. Reduced neointima formation by CD4 antibody treatment in the rat injury model was attributed to effects on macrophage [29]. Vasculitogenic T cells, predominantly CD4\(^+\) that are activated and respond to syngeneic SMCs, have been previously studied. However, these cells were first primed by in vitro exposure to SMCs and then transferred into recipients and shown to cause vasculitogenic injury [30]. This study is unlike our report where the T cell response is transferred into recipients and shown to cause vasculitogenic injury. Thus, our results are the first to directly assess the role of CD4\(^+\) T cells in arterial injury and neointima formation.

CD4\(^-/-\) and CD8\(^-/-\) mice were chosen as donors in the study to assure the purity and specificity of the T cell population transferred into Rag-1\(^-/-\) mice. This is significant given the known interaction between CD4 and CD8 T cells during activation and response. Although the results strongly support a significant role for CD8\(^+\) T cells in inhibiting neointima formation after injury, interpretation must be made with caution in the context of the recipients’ carotid artery. Thus, our results are the first to directly assess the role of CD4\(^+\) T cells in arterial injury and neointima formation.

The specific signaling pathways involved in T cell activation after arterial injury remain to be delineated. However, it has been reported that mice with deficiency in hypoxia-inducible factor 1\(\alpha\) (Hif-1\(\alpha\)) specifically in T cells had increased neointima formation in response to arterial injury [13]. Hif-1 activity is increased in cells subjected to hypoxic conditions [31]. However, Hif-1 activation occurs through both hypoxic and non-hypoxic pathways [32,33], both of which occur after arterial injury. Activation through T cell receptor signaling increases Hif-1\(\alpha\) expression in T cells [34] and T cell function is regulated by Hif-1\(\alpha\) [35]. Hypoxia and inflammation interact in both innate and adaptive immune responses [36] and it is unclear how this interaction factors in neointima formation after arterial injury. For example, it is unknown how dendritic cells respond to hypoxia in our injury model. What may link the two arms of the immune system in the context of hypoxia and inflammation is signaling through the Toll-like receptors. Hif-1\(\alpha\) mediates TLR2 and TLR6 expression [37]. How this relates to arterial injury remains uncertain because of conflicting reports on the role of endogenous TLR2 signaling after arterial injury [38,39] and TLR6 signaling after arterial injury remains to be defined. However, the reported interaction between TLR2 and TLR6 [37] could yet link Hif-1\(\alpha\) activation, TLR signaling, and the immune response to arterial injury.

The limitation of the study is inherent in the model used. The injury performed is on arteries that are neither diseased nor have on-going...
inflammation, thus not completely replicating human stenotic vessels. However, our study shows that CD8\(^+\) T cells control SMC accumulation in the neointima layer of the injured artery, which in the simple case of narrowing of the artery is beneficial. How this activity of CD8\(^+\) T cells may influence an advanced atherosclerotic plaque remains unknown. It also remains unclear what specific activation signal would result in a cytotoxic response of CD8\(^+\) T cells against vascular SMC in the arterial intima, and what makes a relatively small number of SMCs susceptible to targeting by CD8\(^+\) T cells. One possibility is the notion of the “altered-self” phenotype of injured SMCs, which could turn them into target cells of immune surveillance. Altered-self recognition is an essential aspect of homeostasis [27].

In conclusion, the report identifies CD8\(^+\) T cells as the specific and selective T cell type that inhibits neointima formation after arterial injury. There is a surprising lack of direct effect of CD4\(^+\) T cells in the response to arterial injury in the absence of interaction with either B cells or CD8\(^+\) T cells. The findings implicate CD8\(^+\) T cells in regulating neointima formation and warrants further studies of the process that defines this effect.

**Materials and Methods**

**Arterial injury**

Mice were housed in a pathogen-free facility and had ad libitum access to food and water. Aseptic peri-adventitial cuff injury was performed on the right carotid artery of 25 week old male wild type (WT) or Rag-1\(-/-\) mice on the C57Bl6/J background (Jackson Laboratory), as previously described [40]. Briefly, mice were anesthetized with ketamine and xylazine and carprofen was administered prior to surgery for post-surgical pain relief. The right carotid artery was dissected and exposed, and a 2.5 mm-long Tygon tube (internal diameter of 0.51 mm) with a longitudinal opening was placed around the right carotid artery, secured with ligatures around it, and the wound was closed with sutures. A prior report detailed the injury with an electron microscopic study showing that the procedure results in the endothelial layer sloughing off within a week [20]. Uninjured mice served as control. An additional control group of WT mice had sham injury where surgical manipulation of the mice was performed without peri-adventitial cuff injury. Carotid arteries were harvested after perfusion with normal saline for 10 minutes. The Cedars-Sinai Institutional Animal Care and Use Committee approved the experimental protocols specifically used in this study (IACUC # 001552 and 002868).

**Morphometric Analysis**

Frozen sections 6–8 μm thick were collected from the injured carotid arteries of Rag-1\(-/-\) mice, stained with hematoxylin and
eosin, and the vessel area measured as described previously using image analysis software (ImagePro) [16].

**Flow cytometry**

Regional lymph nodes and the spleen were collected and subjected to red blood cell lysis. Cells were then stained with CD4 or CD8b and CD69, CD44, CD25, or CD28 (BD Bioscience) for flow cytometry.

**T cell enrichment and transfer**

Spleen cells from age-matched, donor CD8−/− or CD4−/− mice were pooled. The cells were then negatively selected for T cells using a commercially available kit (Invitrogen) with paramagnetic beads and a magnetic particle concentrator, as recommended by the manufacturer (Dynal). Flow cytometry confirmed cell enrichment with 90.1 ± 2.3% T cells. Equal numbers of cells from either CD4−/− or CD8−/− donors were then injected via the tail vein of Rag-1−/− mice (3 × 10⁷ cells/mouse) 48 hours prior to injury [16]. Age-matched WT mice were also used as CD8+ T cell donors to confirm results from the CD4−/− donors. Cells were collected from lung, lymph node and spleen for flow cytometry 48 hours after cell transfer to assess homing. At least two separate isolation and transfer procedures were performed for each group subjected to arterial injury.

**Characterization of transferred cells**

T cells enriched from CD4−/− donor mouse spleens and T cells enriched from recipient spleens were collected and double-stained for CD8b and CD62L, or CD44 for flow cytometric analysis. Matching isotype antibodies were used as control.

**MHC-I antibody treatment**

MHC-I antibody treatment in CD8+ Tc e l lr e c i p i e n tR a g - 1−/− mice was performed using a mouse monoclonal anti-H-2Db antibody (BD Biosciences; 0.2 mg/mouse, i.p.) on the day of cell transfer, at injury, and twice weekly until day 14. Mouse IgG isotype treatment was used as control. Mice were euthanized 21 days after injury. 

**Immunohistochemistry**

Frozen sections 6–8 μm thick were fixed in ice-cold acetone and stained for CD8b (BD Bioscience). Biotin-conjugated secondary antibody was used for detection and visualized using horseradish peroxidase-conjugated streptavidin and AEC (DAKO). Biotin-conjugated anti-active caspase-3 (BD Bioscience) was used to double stain sections for CD8b and active caspase-3. Detection was performed using alkaline phosphatase-conjugated streptavidin and BCIP/NBT (DAKO). Omission of the primary antibodies was used as negative control.

**SMC lytic assay**

An aliquot of CD8+ T cells negatively purified from 21-day injured CD4−/− mice were co-cultured with CFSE-labeled (1.0 μM) syngeneic aortic smooth muscle cells (SMC) in 10% FBS/DMEM for 4 hours at 37°C at a CD8+ T cell to SMC ratio of 1:1 or 3:1. Basal lysis of SMC without T cells was used as control. Cells were washed in 1 x PBS, trypsinized to detach the SMC monolayer, and stained with 7-AAD for cell lysis as previously described [41]. Flow cytometry was performed on CD8b gated lymphocytes. All values are mean ± SD.

**Table 3. Effect of MHC-I mAb treatment on CD8+ T cells of recipient mouse spleens.**

| MHC-I mAb | IgG isotype |
|-----------|-------------|
| CD8b+ Splenocytes | 20.3±4.6%* | 31.7±5.3% |
| CD8b+CD62L+ Splenocytes | 15.8±2.1% | 14.1±2.4% |
| CD8b+CD44hi Splenocytes | 10.2±2.9%* | 14.5±2.8% |

Analysis was performed on CD8b gated lymphocytes. All values are mean ± SD.

MHC-I mAb (monoclonal antibody) N = 6; IgG isotype N = 5; *p<0.05. doi:10.1371/journal.pone.0020214.t003

**Figure 7. Characterization of cells transferred to recipient Rag-1−/− mice.**

T cells enriched from pooled spleens of CD4−/− mice (Donor CD8b+) were used for flow cytometric analysis and compared with T cells enriched from spleens of CD8b−/− T cell recipient Rag-1−/− mice 48 hours after cell transfer without injury (UI), and 21 days after injury (D21). Representative flow cytometric analysis of CD8b−/− T cells or CD62L or CD44 gated on CD8b+ cells from donor mouse (A). CD8b+CD62L+ (B) and CD8b+CD44hi (C) cells T cells were compared between Donors (N = 3), UI recipients (N = 4) and D21 recipients (N = 4). *P<0.05 vs Donors and UI; †P<0.01 vs Donors and UI. doi:10.1371/journal.pone.0020214.g007

**Table 3. Effect of MHC-I mAb treatment on CD8+ T cells of recipient mouse spleens.**

| MHC-I mAb | IgG isotype |
|-----------|-------------|
| CD8b+ Splenocytes | 20.3±4.6%* | 31.7±5.3% |
| CD8b+CD62L+ Splenocytes | 15.8±2.1% | 14.1±2.4% |
| CD8b+CD44hi Splenocytes | 10.2±2.9%* | 14.5±2.8% |

Analysis was performed on CD8b gated lymphocytes. All values are mean ± SD. MHC-I mAb (monoclonal antibody) N = 6; IgG isotype N = 5; *p<0.05. doi:10.1371/journal.pone.0020214.t003

**Figure 7. Characterization of cells transferred to recipient Rag-1−/− mice.**

T cells enriched from pooled spleens of CD4−/− mice (Donor CD8b+) were used for flow cytometric analysis and compared with T cells enriched from spleens of CD8b−/− T cell recipient Rag-1−/− mice 48 hours after cell transfer without injury (UI), and 21 days after injury (D21). Representative flow cytometric analysis of CD8b−/− T cells or CD62L or CD44 gated on CD8b+ cells from donor mouse (A). CD8b+CD62L+ (B) and CD8b+CD44hi (C) cells T cells were compared between Donors (N = 3), UI recipients (N = 4) and D21 recipients (N = 4). *P<0.05 vs Donors and UI; †P<0.01 vs Donors and UI. doi:10.1371/journal.pone.0020214.g007
performed to detect 7-AAD-stained viable SMCs gated on FL1 (CFSE+). Gating on CFSE assured viability of the cells that were analyzed [41]. Results are presented as % SMC lysis:

\[
\% \text{ SMC Lysis} = \frac{100 \times (\% \text{ Sample Lysis} - \% \text{ Basal Lysis})}{100} - \% \text{ Basal Lysis}
\]

where sample lysis is SMC lysis in the presence of CD8+ T cells at a given effector:target ratio; and basal lysis is SMC lysis without CD8+ T cells [41].

**References**

1. Tanaka T, Soejima H, Hirai N, Sakamoto T, Yoshimura M, et al. (2004) Comparison of frequency of interferon-gamma-positive CD4+ T cells before and after percutaneous coronary intervention and the effect of statin therapy in patients with stable angina pectoris. Am J Cardiol 93: 1347–1349.

2. Brunetti ND, Pepe M, Mennu I, Tocco F, Quagliara D, et al. (2008) Th2-dependent cytokine release in patients treated with coronary angioplasty. Coron Artery Dis 19: 133–137.

3. Sardella G, Gattetakla D, Di RA, Francavilla V, Di RC, et al. (2005) Altered trafficking of CD8+ memory T cells after implantation of rapamycin-eluting stents in patients with coronary artery disease. Immun Lett 96: 85–91.

4. Nakazawa G, Fan AV, Virmani R (2007) Vascular pathology of drug-eluting stents. Heart 92: 274–280.

5. Steffl J, Tanner PC (2007) Biological effects of drug-eluting stents in the coronary circulation. Heart 92: 268–273.

6. Dimayuga PC, Chyu KY, Cercek B (2010) Immune responses regulating the response to arterial injury. Curr Opin Lipidol 21: 416–421.

7. Navarro-Lopez F, Francino A, Serra A, Enjuto M, Reverter JC, et al. (2003) [Late T-lymphocyte and monocyte activation in coronary restenosis. Evidence for a persistent inflammatory/mechanism?]. Rev Esp Cardiol 56: 465–472.

8. Shi Y, Zheng W, Rock KL (2000) Cell injury releases endogenous adjuvants that stimulate cytokotic T cell responses. Proc Natl Acad Sci U S A 97: H390–1495.

9. Wallin RP, Lundqvist A, More SH, von BA, Kicsling R, et al. (2002) Heat-shock proteins as activators of the innate immune system. Trends Immunol 23: 130–135.

10. Strom A, Wigen M, Huldhugard-Nilsos A, Szena A, Gomez MF, et al. (2007) Involvement of the CD11α-natural killer T cell pathway in neointima formation after vascular injury. Circ Res 101: e83–e89.

11. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, et al. (2006) Involvement of CD1d-natural killer T cell pathway in neointima formation in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol Mar 22: 450–455.

12. Kamel IH, Nigro M, Recalde CO, Tanaka H, Athara A, et al. (2002) Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. J Biol Chem 277: 43044–43048.

13. Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML (2001) A novel flow cytometry assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 253: 177–187.

14. Hansson GK, Holm J, Holm S, Fotev Z, Hedrich HJ, et al. (1991) T cell activation and neointima formation in apolipoprotein E-deficient mice. J Biol Chem 266: 48754–48763.

15. Malek TR (2003) The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 74: 961–965.

16. DeGrendele HC, Estes P, Siegelman MH (1997) Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 270: 672–675.

17. Kiefer WC, Jameson SC (1999) Homoeostatic expansion and phenotypic conversion of naive T cells in response to self peptide/MHC ligands. Proc Natl Acad Sci U S A 96: 13506–13511.

18. Schreiber AW, Boguszki LK, Bedrich MJ (2000) Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 192: 557–564.

19. Tyznik A, Sun JG, Benve MJ (2004) The CD4 population in CD4-deficient mice is heavily contaminated with MHC class II-restricted T cells. J Exp Med 199: 559–563.

20. Peng Y, Martin DA, Kenkel J, Zhang K, Ogden CA, et al. (2007) Innate and adaptive immune response to apoptotic cells. J Autoimmun 29: 303–309.

21. Zhou X, Nicoletti A, Elgma R, Hansson GK (2000) Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102: 2919–2922.

22. marryock AW, Adams DH, Wyner LR, Sanyhel MH, Karmosky MJ (1994) CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury. Am J Pathol 145: 1008–1014.

23. Hart MN, Tassell SK, Sadezewski KL, Schelpke RL, Moore SA (1985) Autoimmune vasculitis resulting from in vitro immunization of lymphocytes to smooth muscle. Am J Pathol 119: 448–455.

24. Wang GL, Senzena GL (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 90: 4304–4308.

25. Richard DE, Berra E, Pouyssegur J (2000) Hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 275: 26765–26771.

26. Tynick A, Berra E, Pouyssegur J (2000) Hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 275: 26765–26771.

27. Karvoskova E, Zernecke A, Sevillins G, Millet A, Hristov M, et al. (2007) Expression of HIF-1alpha in injured arteries controls SDF-1alpha-mediated neointima formation in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 27: 2540–2547.

28. Lukashov D, Caldwell C, Allen A, Chen P, Sitkovsky M (2001) Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. J Biol Chem 276: 46754–46763.

29. Lakshav D, Klebanov B, Kojima H, Grinberg A, Olta A, et al. (2000) Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol 177: 4962–4965.

30. Ebertsch HK, Carmellet P (2013) Hypoxia and inflammation. N Engl J Med 364: 656–665.

31. Kuhlilke JF, Frikk JS, Morose-Garcia JC, Rosenberger P, Elschig HK (2007) Hypoxia inducible factor (HIF-1) coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One 2: e1364.

32. Schonfeld HL, Oude Nijhuis MM, van MB, Laman JD, de Kleijn DP, et al. (2005) Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res 66: 162–169.

33. Shihabud S, Nogaki N, Takahashi H, Arimoto T, Niizeki T, et al. (2006) Central memory T lymphocytes in CD4+ T cells is heavily contaminated with MHC class II-restricted T cells. J Exp Med 199: 559–563.

34. Lukashov D, Kaganovska E, Sevillins G, Millet A, Hristov M, et al. (2007) Expression of HIF-1alpha in injured arteries controls SDF-1alpha-mediated neointima formation in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 27: 2540–2547.

35. Richard DE, Berra E, Pouyssegur J (2000) Hypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 275: 26765–26771.

36. Karvoskova E, Zernecke A, Sevillins G, Millet A, Hristov M, et al. (2007) Expression of HIF-1alpha in injured arteries controls SDF-1alpha-mediated neointima formation in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 27: 2540–2547.

37. Lukashov D, Caldwell C, Olta A, Chen P, Sitkovsky M (2001) Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. J Biol Chem 276: 46754–46763.

38. Wang GL, Senzena GL (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 90: 4304–4308.

39. Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML (2001) A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 253: 177–187.